Corpus ID: 26616448

Metoclopramide : A Template for Drug Discovery

@inproceedings{Sanger2017MetoclopramideA,
  title={Metoclopramide : A Template for Drug Discovery},
  author={G. Sanger},
  year={2017}
}
  • G. Sanger
  • Published 2017
  • Metoclopramide was described in 1964 as an anti-emetic drug and stimulant of gastrointestinal motility. Dopamine D2 receptor antagonism explained the anti-emetic activity and was suggested to stimulate gastrointestinal motility. An important use of metoclopramide and other D2 receptor antagonists is to inhibit emesis caused by anticancer chemo radiotherapy. However, the use of new platinum-based anti-cancer drugs led to debilitating emesis, lasting for days and sometimes leading to refusal of… CONTINUE READING
    1 Citations

    References

    SHOWING 1-10 OF 72 REFERENCES
    Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis.
    • 120
    • PDF
    Management of highly emetogenic chemotherapy
    • D. Warr
    • Medicine
    • Current opinion in oncology
    • 2012
    • 12
    Metoclopramide: A Review of its Pharmacological Properties and Clinical Use
    • 107
    Nausea and the quest for the perfect anti-emetic.
    • 61
    Use of ondansetron in palliative medicine.
    • 59
    Translating 5‐HT4 receptor pharmacology
    • G. Sanger
    • Medicine, Chemistry
    • Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
    • 2009
    • 53
    Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics
    • 216
    Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis.
    • 93
    5-hydroxytryptamine m-receptor antagonism to prevent cisplatin-induced emesis
    • 180